26 November 2014

CNS Drug Discovery

Organised by:

SCI's Young Chemists' Panel

Takeda, Cambridge, UK

Registration Closed

This event is no longer available for registration.


This one day event will be held at the heart of the prestigious Cambridge Science Park and will bring together eight speakers from pharmaceutical and biotechnology companies, as well as academia, to focus on the challenges and breakthroughs in drug discovery for disorders of the central nervous system. The event has been tailored to deliver an overview of the medicinal chemistry requirements of centrally-acting drugs and an introduction to hot CNS drug targets.

Several in-depth medicinal chemistry case studies will be presented on the discovery of drug hits, leads and clinical candidates for the treatment of CNS disorders which will include Parkinson’s disease, glioblastoma, Alzheimer’s disease and schizophrenia. Special consideration will be given to designing molecules with brain penetration and applying contemporary approaches to hit generation and lead optimisation, such as fragment screening and structure-based drug design.


The meeting is aimed at scientists in the industrial and academic fields with a background in medicinal chemistry or drug discovery. It is ideally suited to those studying for a postgraduate degree or working in the pharmaceutical or biotechnology industry. This symposium will engage both those who are familiar with medicinal chemistry and drug discovery, and those who are new to the area but interested in learning more.


Day 1

Section 1
Registration and refreshments
CNS drug discovery: a bluffer's guide
Dr Craig Jamieson, University of Strathclyde
An introduction to CNS disorders and targets
Dr Peter Joyce, Vertex
Refreshment break
The discovery of brain penetrant compounds with efficacy in schizophrenia related models
Dr Will Buffham, Takeda
Is L-dopa the best we can do? New approaches to the treatment of Parkinson's disease
Dr Sarah Salvage, King's College London
Phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of glioblastoma: opportunities and challenges
Dr Rob Heald, Argenta
Structure based drug discovery using stabilised GPCRs: application to glutamate receptors
Dr John Christopher, Heptares Therapeutics Ltd
Refreshment break
The challenge of drug discovery in Alzheimer's disease
Dr Mike Hutton, Eli Lilly
The discovery of novel, selective phosphodiesterase 10A (PDE10A) inhibitors from a low molecular weight hit with an unexpected binding mode
Dr Mauro Marigo, Lundbeck
Concluding remarks
Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

Venue and Contact

Takeda Cambridge Ltd

418 Science Park
Milton Road


Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Earlybird fees - before 17 October 2014
GB£80 . . . . ... . . . .SCI Member
GB£25 . . . . . . . . . .SCI Student
GB£55. . . . . . . . . . SCI Subsidised Member
GB£110 . . . . . . . . .Non Member

Standard fees - after 17 October 2014
GB£100 . ... . . . . . .SCI Member
GB£35 . . . . . . . . . .SCI Student
GB£65. . . . . . . . . . SCI Subsidised Member
GB£130 . . . . . . . . .Non Member

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Accredited cpd Centre - The CPD Standards Office - CPD Provider 41057 - www.cpdstandards.com



Additional Info
Exhibition and Sponsorship

An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.